

# CONTENTS

## Contributors

ix

|                                                                                                                                 |           |
|---------------------------------------------------------------------------------------------------------------------------------|-----------|
| <b>1. Classical and Alternative End-Joining Pathways for Repair of Lymphocyte-Specific and General DNA Double-Strand Breaks</b> | <b>1</b>  |
| Cristian Boboila, Frederick W. Alt, and Bjoern Schwer                                                                           |           |
| 1. Introduction                                                                                                                 | 2         |
| 2. V(D)J Recombination                                                                                                          | 4         |
| 3. IgH Class-Switch Recombination                                                                                               | 7         |
| 4. Classical Nonhomologous DNA End Joining                                                                                      | 9         |
| 5. Alternative End Joining                                                                                                      | 21        |
| 6. Perspective                                                                                                                  | 33        |
| Acknowledgments                                                                                                                 | 36        |
| References                                                                                                                      | 36        |
| <b>2. The Leukotrienes: Immune-Modulating Lipid Mediators of Disease</b>                                                        | <b>51</b> |
| Antonio Di Gennaro and Jesper Z. Haeggström                                                                                     |           |
| 1. Introduction                                                                                                                 | 53        |
| 2. Biosynthesis of LTs                                                                                                          | 54        |
| 3. LT Receptors                                                                                                                 | 59        |
| 4. LTs in Immune Responses                                                                                                      | 63        |
| 5. 5-LO and LTs in Human Diseases                                                                                               | 68        |
| 6. Antileukotriene Drugs                                                                                                        | 78        |
| 7. Conclusions                                                                                                                  | 80        |
| Acknowledgments                                                                                                                 | 81        |
| References                                                                                                                      | 81        |
| <b>3. Gut Microbiota Drives Metabolic Disease in Immunologically Altered Mice</b>                                               | <b>93</b> |
| Benoit Chassaing, Jesse D. Aitken, Andrew T. Gewirtz, and Matam Vijay-Kumar                                                     |           |
| 1. Gut Microbiota: The Organ Within the Organ                                                                                   | 94        |
| 2. Localization and Restricted Signaling of PRRs Protects against Aberrant Gut Inflammation                                     | 97        |
| 3. Role of Microbiota in Metabolic Disease                                                                                      | 98        |

|                                                                                         |            |
|-----------------------------------------------------------------------------------------|------------|
| 4. Increased Energy Harvesting by Microbiota in the Development of Metabolic Disease    | 99         |
| 5. Microbiota-Induced Sub-Clinical Gut Inflammation Causes Metabolic Disease            | 100        |
| 6. Microbiota Generates Toxic Metabolites from the Diet, Resulting in Metabolic Disease | 104        |
| 7. Microbiota-Mediated Metabolic Disease in Absence of Inflammasome Signaling           | 105        |
| 8. Microbiota-Mediated Metabolic Disease in Absence of Adaptative Immunity              | 106        |
| 9. Manipulating the Gut Microbiome, Therapeutic Strategies for Obesity                  | 107        |
| 10. Unanswered Questions, Future Directions, and Conclusions                            | 108        |
| References                                                                              | 108        |
| <b>4. What is Unique About the IgE Response?</b>                                        | <b>113</b> |
| Huizhong Xiong, Maria A. Curotto de Lafaille, and Juan J. Lafaille                      |            |
| 1. Effector Functions of IgE Antibodies                                                 | 114        |
| 2. Control of Class Switch Recombination to IgE                                         | 116        |
| 3. Direct and Sequential Switching to IgE                                               | 119        |
| 4. IgE <sup>+</sup> Cells and Germinal Centers                                          | 121        |
| 5. Germinal Center Versus Plasma Cell Fates: Bcl6 and Blimp1                            | 122        |
| 6. Studying IgE Responses <i>In Vivo</i>                                                | 124        |
| 7. IgE Cytoplasmic Tail and Germinal Centers                                            | 128        |
| 8. Is There a Memory IgE <sup>+</sup> Cell?                                             | 130        |
| 9. Direct and Sequential Switching to IgE in Immature and Mature B Cells                | 132        |
| 10. Human Immunodeficiencies with High IgE Production                                   | 133        |
| 11. Concluding Remarks                                                                  | 135        |
| Acknowledgments                                                                         | 135        |
| References                                                                              | 136        |
| <b>5. Prostanoids as Regulators of Innate and Adaptive Immunity</b>                     | <b>143</b> |
| Takako Hirata and Shuh Narumiya                                                         |            |
| 1. Introduction                                                                         | 144        |
| 2. Prostanoid Receptors                                                                 | 146        |
| 3. Prostanoids and Innate Immunity                                                      | 156        |
| 4. Prostanoids and Adaptive Immunity                                                    | 161        |
| 5. Prostanoids in Immunopathology                                                       | 163        |
| 6. Targeting of Prostanoid Receptors                                                    | 164        |
| 7. Concluding Remarks                                                                   | 165        |
| Acknowledgments                                                                         | 165        |
| References                                                                              | 166        |

## 6. Lymphocyte Development: Integration of DNA Damage Response Signaling

175

Jeffrey J. Bednarski and Barry P. Sleckman

- |                                                                                          |     |
|------------------------------------------------------------------------------------------|-----|
| 1. Lymphocyte Antigen Receptor Gene Assembly                                             | 176 |
| 2. DNA Damage Responses                                                                  | 179 |
| 3. Responses to RAG-Mediated DNA DSBs                                                    | 183 |
| 4. Integrating RAG DSB-Mediated Signals with Other B Lymphocyte<br>Developmental Signals | 188 |
| 5. Concluding Remarks                                                                    | 194 |
| Acknowledgments                                                                          | 195 |
| References                                                                               | 195 |

## Index

205

### Contents of Recent Volumes

213